GSK is pumping £50 million (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge ...

In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the ...

A higher abundance of monocyte-derived alveolar macrophages significantly correlated with worse lung fibrosis in RPRA ...

AN INSIGHTFUL session on the future of lung transplantation presented at this year’s European Respiratory Society (ERS) ...

Emily Pink, 21, has cystic fibrosis, a rare genetic disorder that causes a build-up of sticky mucus in her lungs and ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. | ...

Insilico Medicine’s ISM001-055 was generally safe and improved lung function in people with idiopathic pulmonary fibrosis ...

Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) is a specific form of interstitial lung disease characterized by progressive lung scarring, which leads to significant ...

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and (BMC) have announced a new collaboration with the global biopharma company GSK to advance innovative research ...

New drugs for the lung disease are allowing people to live much longer with the condition, which historically was often fatal ...

In propensity score-matched cohorts of 121,046 hospitalized patients, those with RA and T2D had an ILD prevalence of 2.25%, ...

The RespiriNTM project has received funding from the Innovative Health Initiative 2 Joint Undertaking (JU) under grant agreement No 853932. This Joined Undertaking receives support from the European ...